Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis

Multiple Sclerosis

Volumn 14, Issue 7, 2008, Pages 981-984

  Sellner, Johann ^a,b   Greeve, I ^a   Mattle, H P ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anti inflammatory; Atorvastatin; C reactive protein; Multiple sclerosis

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; INTERFERON BETA SERINE; BETA INTERFERON; BIOLOGICAL MARKER; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA-1B; PYRROLE DERIVATIVE;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; ADOLESCENT; ADULT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG INTERACTION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PYRROLES;

EID: 54449086499     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508091368     Document Type: Article

References (14)

1. Gabay C Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
2. Pasceri V Willerson JT Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
3. Giovannoni G Miller DH Losseff NA. Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis. J Neurol 2001;248:487-495.
4. Soilu-Hanninen M Koskinen JO Laaksonen M Hanninen A Lilius EM Waris M. High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology 2005;65:153-155.
5. Abeles AM Pillinger MH. Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy. Arthritis Rheum 2006;54:393-407.
6. Boylan MT Crockard AD Duddy ME Armstrong MA McMillan SA Hawkins SA. Interferon-beta1a administration results in a transient increase of serum amyloid A protein and C-reactive protein: Comparison with other markers of inflammation. Immunol Lett 2001;75:191-197.
7. Osman R L'Allier PL Elgharib N Tardif JC. Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vasc Health Risk Manag 2006;2:221-237.
8. Giovannoni G Thorpe JW Kidd D. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 1996;60:20-26.
9. Nicoletti F Di Marco R Patti F. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha. Cytokine 2000;12:682-687.
10. Montalban X Duran I Rio J Saez-Torres I Tintore M Martinez-Caceres EM. Can we predict flu-like symptoms in patients with multiple sclerosis treated with interferon-beta. J Neurol 2000;247:259-262.
11. Nakatsuji Y Nakano M Moriya M. Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection. Cytokine 2006;36:69-74.
12. Kwak BR Mulhaupt F Mach F. Atherosclerosis: Anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev. 2003;2:332-338.
13. Dhawan N Reder A. Statins block interferon signaling in human immune cells: Potential loss of the therapeutic effect of IFN beta in multiple sclerosis. Neurology. 2007;68(Suppl1):A364.
14. Zhang D Sun M Samols D Kushner I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem. 1996;271:9503-9509.